5.19

5.81% -0.32

After Hours: 5.20 0.010 +0.19%

Trisalus Life Sciences Inc (TLSI)

Overview News Price History Discussions Forecast

Trisalus Life Sciences Inc stock is traded at $5.19, with a volume of 29,613. It is down -5.81% in the last 24 hours and up +0.97% over the past month. TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

Previous Close:

$5.51

Open:

$5.49

24h Volume:

29,613

Relative Volume:

0.61

Market Cap:

$211.14M

Revenue:

$15.33M

Net Income/Loss:

$-40.19M

P/E Ratio:

-2.962

EPS:

-1.7522

Net Cash Flow:

1W Performance:

-6.99%

1M Performance:

+0.97%

6M Performance:

+36.22%

1Y Performance:

-12.33%

1-Day Range:

$5.19

$5.50

1-Week Range:

$5.08

$5.58

52-Week Range:

$3.50

$6.08

Trisalus Life Sciences Inc Stock (TLSI) Company Profile

Name

Trisalus Life Sciences Inc

Sector

Healthcare (1172)

Industry

Medical Devices (150)

Phone

415 336 8917

Address

6272 WEST 91ST AVENUE, WESTMINSTER

Employee

110

Twitter

Next Earnings Date

Latest SEC Filings

TLSI's Discussions on Twitter

Compare TLSI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TLSI Trisalus Life Sciences Inc	5.19	211.14M	15.33M	-40.19M	0	-1.7522
ABT Abbott Laboratories	132.28	233.36B	42.34B	13.50B	6.66B	7.71
SYK Stryker Corp	373.37	147.15B	23.22B	2.86B	3.58B	7.40
BSX Boston Scientific Corp	101.73	146.97B	17.55B	2.03B	2.72B	1.37
MDT Medtronic Plc	86.17	112.76B	33.54B	4.66B	5.19B	3.62
EW Edwards Lifesciences Corp	73.27	44.46B	5.54B	4.18B	623.10M	7.00

Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-13-25	Initiated	Lake Street	Buy
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight
Nov-11-24	Initiated	ROTH MKM	Buy
Oct-25-24	Initiated	Northland Capital	Outperform
Sep-16-24	Initiated	Oppenheimer	Outperform
May-30-24	Initiated	Canaccord Genuity	Buy

View All

Trisalus Life Sciences Inc Stock (TLSI) Latest News

Jun 17, 2025

TriSalus Life Sciences (NASDAQ:TLSIW) Stock Price Down 7.1% – Should You Sell? - Defense World

Jun 17, 2025

Jun 16, 2025

TriSalus shareholders elect directors, ratify auditor By Investing.com - Investing.com South Africa

Jun 16, 2025

Cantor Fitzgerald maintains $9 target on TriSalus stock By Investing.com - Investing.com Nigeria

Jun 10, 2025

Millennium Management LLC Cuts Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World

Jun 10, 2025

Jun 09, 2025

Cantor Fitzgerald maintains $9 target on TriSalus stock - Investing.com

Jun 09, 2025

Jun 08, 2025

Bank of America Corp DE Raises Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World

Jun 08, 2025

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Jun 08, 2025

Jun 04, 2025

TriSalus Launches TriNav FLX To Enhance Drug Delivery In Complex Peripheral Vessels - Nasdaq

Jun 04, 2025

TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System - Bluefield Daily Telegraph

Jun 04, 2025

TriSalus Unveils Next-Gen Cancer Treatment Device: New TriNav FLX Shows 28% Better Navigation - Stock Titan

Jun 04, 2025

Northern Trust Corp Has $161,000 Position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World

Jun 04, 2025

Jun 02, 2025

Cantor Fitzgerald maintains TriSalus stock rating after CFO change By Investing.com - Investing.com South Africa

Jun 02, 2025

Cantor Fitzgerald maintains TriSalus stock rating after CFO change - Investing.com

Jun 02, 2025

TriSalus Life Sciences names new CFO - BizWest

Jun 02, 2025

May 31, 2025

TriSalus Life Sciences (TLSI) Plans to Offer 5.5M Shares of Comm - GuruFocus

May 31, 2025

May 30, 2025

TriSalus Life Sciences (TLSI) Names New Chief Financial Officer - GuruFocus

May 30, 2025

TriSalus Life Sciences (TLSI) Plans to Offer 5.5M Shares of Common Stock | TLSI Stock News - GuruFocus

May 30, 2025

TriSalus Life Sciences Appoints David Patience as CFO - marketscreener.com

May 30, 2025

TriSalus Life Sciences Appoints David Patience To Succeed James Young As CFO - Nasdaq

May 30, 2025

TriSalus Names David Patience Finance Chief as James Young Departs - MarketWatch

May 30, 2025

TriSalus Life Sciences appoints new CFO amid transition - Investing.com

May 30, 2025

TriSalus Life Sciences, Inc. Announces Chief Financial Officer Changes - marketscreener.com

May 30, 2025

TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience - Business Wire

May 30, 2025

May 24, 2025

TriSalus Life Sciences (NASDAQ:TLSIW) Stock Price Up 3.9% – Should You Buy? - Defense World

May 24, 2025

Roth Capital Issues Negative Estimate for TLSI Earnings - Defense World

May 24, 2025

May 22, 2025

TLSI FY2025 EPS Estimate Reduced by Cantor Fitzgerald - Defense World

May 22, 2025

May 19, 2025

TriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable market - MSN

May 19, 2025

May 18, 2025

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q1 2025 Earnings Call Transcript - MSN

May 18, 2025

May 17, 2025

Analysts Set TriSalus Life Sciences, Inc. (NASDAQ:TLSI) PT at $10.93 - Defense World

May 17, 2025

May 16, 2025

Trisalus Life Sciences Q1 2025 Earnings Call Highlights - TipRanks

May 16, 2025